Talaroconvolutin A is an inducer of ferroptosis (ferroptosis) that operates by elevating reactive oxygen species (ROS) levels instead of acting through the GPX4 pathway. It decreases the expression of the solute carrier family 7 member 11 (SLC7A11) and increases the expression of arachidonate lipoxygenase 3 (ALOXE3). This compound inhibits the growth of colorectal cancer cells HCT116 and bladder cancer cells SW480, with IC50 values of 1.22 μM and 1.4 μM, respectively. Talaroconvolutin A is applicable in studies related to colorectal and bladder cancers.

Talaroconvolutin A, when used in varying concentrations and durations, inhibits the growth of HCT116, SW480, SW620, SW780, and UM-UC-3 cell lines with IC50 values of 9.23, 8.15, and 5.82 μM in 10% FBS medium, and 1.22, 1.40, and 1.27 μM in 1% FBS medium across these lines. It reduces DNA synthesis in HCT116 and SW480 cells over 48 hours and inhibits SW480 cell growth, induces cell death, and increases ROS levels without causing apoptosis or cell cycle arrest. Additionally, Talaroconvolutin A at 5 μM induces ferroptosis and enhances oxidative stress through increased lipid peroxidation in SW480 cells, while modulating SLC7A11 expression and boosting ALOXE3 mRNA and protein levels. The compound also suppresses proliferation, DNA replication, and colony formation in SW780 cells while inducing ferroptosis via ROS without significant apoptosis. Biotin binding does not compromise its anticancer activity, as shown by its effects on SW780 and UM-UC-3 cells. Further, Talaroconvolutin A affects MAPK1 and MAPK14 kinase activity, promoting phosphorylation changes in proteomics, and inhibits HeLa, BEL-7042 cells, and α-glucosidase activity with IC50s of 14.9, 26.7, and 78.2 μM, respectively.

Talaroconvolutin A, administered at 6 mg/kg via intraperitoneal injection every other day for a period of 40 days, inhibits the growth of tumors derived from the HCT116 cell line in Balb/c nude mice. Additionally, Talaroconvolutin A, given under the same dosage and frequency of administration for 24 days, suppresses bladder tumor growth in xenograft mouse models.